BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
Go back to BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)| BIOLINE RX SP ADR (NASDAQ: BLRX) | Delayed: 2.49 -0.04 (1.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.53 | 52 Week High | $1.63 | |||
| Open | $2.50 | 52 Week Low | $0.71 | |||
| Day High | $2.51 | P/E | N/A | |||
| Day Low | $2.44 | EPS | $0.00 | |||
| Volume | 2,752 | |||||
